Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Pfizer Japan Taps COO Hiroo Igarashi as New Skipper
November 18, 2024
- Dispensing Costs for Top LLPs Fall over 30% after Elective Care Rollout: Intage
November 18, 2024
- Shipment Curbs Growing for Strattera Generics amid Nitrosamine Issues
November 18, 2024
- MSD Files Silgard 9 for Male Use in Japan
November 18, 2024
- Pfizer’s JN.1 COVID Jabs for Children, Infants Now Available in Japan
November 18, 2024
- Kaken Snags Option Rights to Numab’s IBD Drug in Asia
November 18, 2024
- Alexion Japan Wants to Extend 2-Digit Growth, Ride on Reform Boon: Next Chief
November 15, 2024
- EMA Backs Leqembi after Re-Examination, but for Limited Use
November 15, 2024
- Stella Pharma Ties Up with TLS for Borofalan in US, Europe
November 15, 2024
- MSD Files PAH Treatment Sotatercept in Japan
November 15, 2024
- Keytruda Maintains Top-Selling Title in Japan in July-September: IQVIA
November 14, 2024
- Mitsubishi Chemical Looking for “Best Partners” for Pharma Biz: CEO
November 14, 2024
- Lilly Japan Halts Manufacturing of Strattera over Nitrosamine Impurities
November 14, 2024
- Nippon Shinyaku Bags Japan, US Rights to Atsena’s Gene Therapy
November 14, 2024
- Daiichi Sankyo Replaces FDA Lung Cancer Filing for TROP2-Directed ADC
November 13, 2024
- Pfizer’s Antibiotic Zavicefta Now Available in Japan
November 13, 2024
- Terumo Rolls Out Anapeine Generics after Expedited Listing
November 13, 2024
- Moderna Sees CMV, EBV Vaccines as “Significant Assets”: Medical Affairs Chief
November 12, 2024
- Amvuttra Filed for ATTR-CM in Japan: Alnylam
November 12, 2024
- Japan Ethical Drug Sales Down 0.4% in September: Crecon
November 12, 2024
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…